Form 4: Benitec Biopharma CEO Jerel A. Banks Acquires Options

Benitec Biopharma Inc. CEO Jerel A. Banks reports acquiring options to purchase 466,554 shares of common stock.

Summary

• Jerel A. Banks, CEO of Benitec Biopharma Inc., filed a Form 4 on March 8, 2024, reporting a transaction on March 6, 2024.
• Banks acquired options to purchase 466,554 shares of Benitec Biopharma's common stock at an exercise price of $5.21.
• These options vest in three equal installments on March 6, 2025, March 6, 2026, and March 6, 2027.
• Following the transaction, Banks directly owns options for 466,554 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it's a standard regulatory filing. The CEO acquiring options is generally a positive sign, but it's not a major event.

Positives

• The CEO's acquisition of options could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in the biopharmaceutical industry.

Comparison to Industry Standards

• Option grants are a standard component of executive compensation packages in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen routinely grant stock options to their executives as part of their overall compensation strategy.
• The vesting schedule of three years is also typical for such grants.

Stakeholder Impact

• The acquisition of options by the CEO could have a minor positive impact on shareholder sentiment.

Key Dates